EC Gastroenterology and Digestive System

Case Report Volume 11 Issue 1 - 2024

Resolution of Eczema with Vedolizumab in an Ulcerative Colitis Patient

Qinglu Yang and Xiaomin Sun*

1Department of Gastroenterology, The Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
*Corresponding Author: Xiaomin Sun, Department of Gastroenterology, The Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China.
Received: December 27, 2023; Published: January 10, 2023




Up to 35% of patients with ulcerative colitis have extra-intestinal manifestations (EIMs), of which approximately 15% are often associated with cutaneous involvement [1-3]. The therapeutic effect of vedolizumab, intestinal selective biologic, on EIMs in patients with inflammatory bowel disease remains unclear [4]. In particular, there are still only few data on the role of vedolizumab in the treatment of dermatologic EIMs, and its efficacy remains debatable [5]. We describe here a case of vedolizumab successfully resolving dermatologic EIMs in a patient with ulcerative colitis.

 Keywords: Ulcerative Colitis; Vedolizumab; Extra-Intestinal Manifestations

Qinglu Yang and Xiaomin Sun. “Resolution of Eczema with Vedolizumab in an Ulcerative Colitis Patient".  11.1 (2024): 01-03.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net